Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
Am J Clin Nutr. 2020 Dec 10;112(6):1642-1652. doi: 10.1093/ajcn/nqaa245.
Antioxidants have been promoted for cardiovascular disease (CVD) risk reduction and for the prevention of cancer. Our preliminary analysis suggested that only when selenium was present were antioxidant mixtures associated with reduced all-cause mortality.
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to determine the effect of selenium supplementation alone and of antioxidant mixtures with or without selenium on the risk of CVD, cancer, and mortality.
We identified studies using the Cochrane Library, Medline, and Embase for potential CVD outcomes, cancer, and all-cause mortality following selenium supplementation alone or after antioxidant supplement mixtures with and without selenium up to June 5, 2020. RCTs of ≥24 wk were included and data were analyzed using random-effects models and classified by the Grading of Recommendations, Assessment, Development, and Evaluation approach.
The meta-analysis identified 9423 studies, of which 43 were used in the final analysis. Overall, no association of selenium alone or antioxidants was seen with CVD and all-cause mortality. However, a decreased risk with antioxidant mixtures was seen for CVD mortality when selenium was part of the mix (RR: 0.77; 95% CI: 0.62, 0.97; P = 0.02), with no association when selenium was absent. Similarly, when selenium was part of the antioxidant mixture, a decreased risk was seen for all-cause mortality (RR: 0.90; 95% CI: 0.82, 0.98; P = 0.02) as opposed to an increased risk when selenium was absent (RR: 1.09; 95% CI: 1.04, 1.13; P = 0.0002).
The addition of selenium should be considered for supplements containing antioxidant mixtures if they are to be associated with CVD and all-cause mortality risk reduction. This trial was registered at https://www.crd.york.ac.uk/PROSPERO/ as CRD42019138268.
抗氧化剂已被推广用于降低心血管疾病 (CVD) 风险和预防癌症。我们的初步分析表明,只有当存在硒时,抗氧化剂混合物才与全因死亡率降低相关。
我们进行了一项系统评价和荟萃分析,以确定单独补充硒以及含有或不含有硒的抗氧化剂混合物对 CVD、癌症和死亡率风险的影响。
我们使用 Cochrane 图书馆、Medline 和 Embase 来确定研究,以评估单独补充硒或补充含有和不含有硒的抗氧化剂混合物后,直至 2020 年 6 月 5 日的 CVD 结局、癌症和全因死亡率的潜在影响。纳入了 ≥24 周的随机对照试验,并使用随机效应模型进行数据分析,并根据推荐评估、制定与评价分级法进行分类。
荟萃分析确定了 9423 项研究,其中 43 项用于最终分析。总体而言,单独补充硒或抗氧化剂与 CVD 和全因死亡率无关。然而,当硒是混合物的一部分时,抗氧化剂混合物与 CVD 死亡率的风险降低相关(RR:0.77;95%CI:0.62,0.97;P=0.02),而当硒不存在时则没有关联。同样,当硒是抗氧化剂混合物的一部分时,全因死亡率的风险降低(RR:0.90;95%CI:0.82,0.98;P=0.02),而当硒不存在时则增加风险(RR:1.09;95%CI:1.04,1.13;P=0.0002)。
如果含有抗氧化剂混合物的补充剂要与 CVD 和全因死亡率风险降低相关,则应考虑添加硒。本试验在 https://www.crd.york.ac.uk/PROSPERO/ 注册,注册号为 CRD42019138268。